Research ArticleOriginal Article
Open Access

Cyclooxygenase-2 immunohistochemical expression is associated with worse prognosis in breast cancer

Retrospective study and literature review

Jaudah Al-Maghrabi and Mohamad N. Khabaz
Saudi Medical Journal July 2022, 43 (7) 687-693; DOI: https://doi.org/10.15537/smj.2022.43.7.20220052

References

  1. 1.↵
    1. Warner TD,
    2. Mitchell JA.
    Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci U S A 2002; 99: 13371–13373.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Ramsay RG,
    2. Ciznadija D,
    3. Vanevski M,
    4. Mantamadiotis T.
    Transcriptional regulation of cyclo-oxygenase expression: 3 pillars of control. Int J Immunopathol Pharmacol 2003; 16: 59–67.
    OpenUrlPubMed
  3. 3.↵
    1. Hashemi Goradel N,
    2. Najafi M,
    3. Salehi E,
    4. Farhood B,
    5. Mortezaee K.
    Cyclooxygenase-2 in cancer: a review. J Cell Physiol 2019; 234: 5683–5699.
    OpenUrl
  4. 4.↵
    1. Appleby SB,
    2. Ristimäki A,
    3. Neilson K,
    4. Narko K,
    5. Hla T.
    Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302: 723–727.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Kurumbail RG,
    2. Stevens AM,
    3. Gierse JK,
    4. McDonald JJ,
    5. Stegeman RA,
    6. Pak JY, et al.
    Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644–648.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Dannenberg AJ,
    2. Lippman SM,
    3. Mann JR,
    4. Subbaramaiah K,
    5. DuBois RN.
    Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254–266.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Xu Y,
    2. Yang X,
    3. Wang T,
    4. Yang L,
    5. He YY,
    6. Miskimins K, et al.
    Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-γ-linolenic acid peroxidation dependent mechanism. BMC Cancer 2018; 18: 330.
    OpenUrl
  8. 8.
    1. Qiu HY,
    2. Wang PF,
    3. Li Z,
    4. Ma JT,
    5. Wang XM,
    6. Yang YH, et al.
    Synthesis of dihydropyrazole sulphonamide derivatives that act as anti-cancer agents through COX-2 inhibition. Pharmacol Res 2016; 104: 86–96.
    OpenUrl
  9. 9.↵
    1. Charalambous MP,
    2. Maihöfner C,
    3. Bhambra U,
    4. Lightfoot T,
    5. Gooderham NJ.
    Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br J Cancer 2003; 88: 1598–1604.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Harris RE,
    2. Casto BC,
    3. Harris ZM.
    Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol 2014; 5: 677–692.
    OpenUrlCrossRefPubMed
  11. 11.
    1. Misra S,
    2. Sharma K.
    COX-2 signaling and cancer: new players in old arena. Curr Drug Targets 2014; 15: 347–359.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Wang D,
    2. Dubois RN.
    Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181–193.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Hung JH,
    2. Su IJ,
    3. Lei HY,
    4. Wang HC,
    5. Lin WC,
    6. Chang WT, et al.
    Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem 2004; 279: 46384–46392.
    OpenUrlAbstract/FREE Full Text
  14. 14.
    1. Montezuma MAP,
    2. Fonseca FP,
    3. Benites BM,
    4. Soares CD,
    5. do Amaral-Silva GK,
    6. de Almeida OP, et al.
    COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma. Pathol Res Pract 2018; 214: 907–913.
    OpenUrl
  15. 15.↵
    1. Höing B,
    2. Kanaan O,
    3. Altenhoff P,
    4. Petri R,
    5. Thangavelu K,
    6. Schlüter A, et al.
    Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma. Oncotarget 2018; 9: 8415–8426.
    OpenUrl
  16. 16.↵
    1. Li J,
    2. Zhou Y,
    3. Wang H,
    4. Gao Y,
    5. Li L,
    6. Hwang SH, et al.
    COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor. Oncotarget 2017; 8: 87353–87363.
    OpenUrlCrossRef
  17. 17.↵
    1. Chen Y,
    2. Wang J.
    Expression and significance of carcinoembryonic antigen, cancer antigen 153, and cyclooxygenase-2 in breast cancer. Oncology and Translational Medicine 2017; 3: 25–30.
    OpenUrl
  18. 18.↵
    1. Wang G-P,
    2. Li Y,
    3. Ding Z-J,
    4. Liang Y-A,
    5. Hou S-C.
    Significance of COX-2, HIF-1α, CA153 and CA125 for breast cancer prognosis and evaluation of therapeutic effects. Acta Medica Mediterranea 2016; 32: 599–606.
    OpenUrl
  19. 19.↵
    1. Muhammad MS,
    2. Edin HS,
    3. Guirguis MN,
    4. Osman SM.
    Immunohistochemical cyclooxygenase-2 (COX-2) and P53 expression in breast carcinoma with correlation to clinico-pathological parameters. Med J Cairo Univ 2013; 81: 253–266.
    OpenUrl
  20. 20.↵
    1. Jana D,
    2. Sarkar DK,
    3. Ganguly S,
    4. Saha S,
    5. Sa G,
    6. Manna AK, et al.
    Role of cyclooxygenase 2 (COX-2) in prognosis of breast cancer. Indian J Surg Oncol 2014; 5: 59–65.
    OpenUrlPubMed
  21. 21.↵
    1. Bhutani N,
    2. Moga S,
    3. Poswal P,
    4. Sharma B,
    5. Arora S,
    6. Singla S.
    COX-2 expression in carcinoma of the breast and surrounding non-neoplastic beast tissue. Arch Breast Cancer 2021; 8: 29–36.
    OpenUrl
  22. 22.↵
    1. Sharma A,
    2. Marwah N,
    3. Parmar P,
    4. Sen R.
    Expression of COX-2 in carcinoma breast. J Clin Diagn Res 2018; 12: 10–14.
    OpenUrl
  23. 23.↵
    1. Tekin L,
    2. Çelik SY.
    Immunohistochemical expression of cyclooxygenase-2 and its relationship with prognostic parameters in breast cancer. Cyprus J Med Sci 2021; 6: 39–43.
    OpenUrl
  24. 24.↵
    1. Nassar MIA,
    2. Bebars SMM,
    3. Said RMS,
    4. Mustafa TMA.
    Immunohistochemical expression of cyclooxygenase-2 (COX-2) in breast cancer. Egypt J Hosp Med 2019; 75: 2397–2405.
    OpenUrl
  25. 25.
    1. Ameen MAM,
    2. Jalal JA,
    3. Alnuaimy WMT.
    Cyclooxygenase-2 immunoexpression in invasive breast Carcinoma: a possible prognostic factor. AMJ 2018; 4: 36–40.
    OpenUrl
  26. 26.↵
    1. Solanki R,
    2. Agrawal N,
    3. Ansari M,
    4. Jain S,
    5. Jindal A.
    COX-2 expression in breast carcinoma with correlation to clinicopathological parameters. Asian Pac J Cancer Prev 2018; 19: 1971–1975.
    OpenUrl
  27. 27.↵
    1. Gao S,
    2. Sun Y,
    3. Liu X,
    4. Zhang D,
    5. Yang X.
    EpCAM and COX–2 expression are positively correlated in human breast cancer. Mol Med Rep 2017; 15: 3755–3760.
    OpenUrl
  28. 28.↵
    1. Sicking I,
    2. Rommens K,
    3. Battista MJ,
    4. Böhm D,
    5. Gebhard S,
    6. Lebrecht A, et al.
    Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients. BMC Cancer 2014; 14: 952.
    OpenUrl
  29. 29.↵
    1. Giaginis C,
    2. Sampani A,
    3. Kotta-Loizou I,
    4. Giannopoulou I,
    5. Danas E,
    6. Politi E, et al.
    Elevated Hu-antigen receptor (HuR) expression is associated with tumor aggressiveness and poor prognosis but not with COX-2 expression in invasive breast carcinoma patients. Pathol Oncol Res 2018; 24: 631–640.
    OpenUrl
  30. 30.↵
    1. Simonsson M,
    2. Björner S,
    3. Markkula A,
    4. Nodin B,
    5. Jirström K,
    6. Rose C, et al.
    The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size. Int J Cancer 2017; 140: 163–175.
    OpenUrlCrossRef
  31. 31.↵
    1. Misron NA,
    2. Looi LM,
    3. Nik Mustapha NR.
    Cyclooxygenase-2 expression in invasive breast carcinomas of no special type and correlation with pathological profiles suggest a role in tumorigenesis rather than cancer progression. Asian Pac J Cancer Prev 2015; 16: 1553–1558.
    OpenUrl
  32. 32.↵
    1. Serra KP,
    2. Peres RM,
    3. Sarian LO,
    4. Vassallo J,
    5. Pinto GA,
    6. Silva GR, et al.
    Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival. Acta Histochem 2016; 118: 176–182.
    OpenUrlCrossRef
  33. 33.↵
    1. Aggarwal A,
    2. Al-Rohil RN,
    3. Batra A,
    4. Feustel PJ,
    5. Jones DM,
    6. DiPersio CM.
    Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer. BMC Cancer 2014; 14: 459.
    OpenUrl
  34. 34.↵
    American Cancer Society. Cancer facts & figures 2014. [updated 2014; accessed 2021 Dec 20]. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2014.html
  35. 35.↵
    1. Al-Zahrani W,
    2. Al-Shahrani Z,
    3. Al-Madouj A,
    4. Hayder M,
    5. Al-Shridah M,
    6. Al-Shumrani T.
    Cancer Incidence Report Saudi Arabia 2012. Saudi Health Coucil 2018; 9: 1–84.
    OpenUrl
  36. 36.↵
    1. Tan PH,
    2. Ellis I,
    3. Allison K,
    4. Brogi E,
    5. Fox SB,
    6. Lakhani S, et al.
    The 2019 World Health Organization classification of tumours of the breast. Histopathology 2020; 77: 181–185.
    OpenUrlPubMed
  37. 37.↵
    1. Amin MB,
    2. Greene FL,
    3. Edge SB,
    4. Compton CC,
    5. Gershenwald JE, et al.
    The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93–99.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Al-Maghrabi J,
    2. Buhmeida A,
    3. Emam E,
    4. Syrjänen K,
    5. Sibiany A,
    6. Al-Qahtani M, et al.
    Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma. World J Gastroenterol 2012; 18: 1793–1799.
    OpenUrlPubMed
  39. 39.↵
    1. Al-Maghrabi J,
    2. Emam E,
    3. Gomaa W,
    4. Saggaf M,
    5. Buhmeida A,
    6. Al-Qahtani M, et al.
    c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence. BMC Cancer 2015; 15: 676.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords